<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><description>乘之愈往，识之愈真。如将不尽，与古为新。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 08 Jun 2021 15:31:44 +0800</pubDate><image><url>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</url><title>医药笔记 | wechat-feeds</title><link>http://MzI4MzQyMjM0Ng.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限</title><link>https://mp.weixin.qq.com/s/dtGouCxDWCfsZkXwrBKS7w</link><description></description><content:encoded><![CDATA[亚盛医药APG-2575临床优势初显，国内首家Bcl-2抑制剂前景无限]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Moderna 偏向性IL-2 mRNA启动临床研究</title><link>https://mp.weixin.qq.com/s/6wr9qpg7MwQ9SkWdupP-6g</link><description></description><content:encoded><![CDATA[Moderna 偏向性IL-2 mRNA启动临床研究]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>国内首家：健信生物申报PD-1/TIM-3双抗</title><link>https://mp.weixin.qq.com/s/uedxEvAS2Q1pBJ06ENd-xw</link><description></description><content:encoded><![CDATA[国内首家：健信生物申报PD-1/TIM-3双抗]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：纳米抗体攻克新冠突变体</title><link>https://mp.weixin.qq.com/s/-FcFdNqUxsIR65GJu1tWjw</link><description></description><content:encoded><![CDATA[Nature：纳米抗体攻克新冠突变体]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：癌症细胞疗法统计</title><link>https://mp.weixin.qq.com/s/YwA2twoAbQAtuHOo6a-Bmw</link><description></description><content:encoded><![CDATA[Nature：癌症细胞疗法统计]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>Nature：癌症细胞因子疗法全景图</title><link>https://mp.weixin.qq.com/s/7825zNA6xz7zTkC7ip6yNA</link><description></description><content:encoded><![CDATA[Nature：癌症细胞因子疗法全景图]]></content:encoded><pubDate>Tue, 08 Jun 2021 14:42:41 +0800</pubDate></item><item><title>乐普生物差异化PD-1单抗，临床优势初显</title><link>https://mp.weixin.qq.com/s/KntbXNNM1_5yoInPVwHm2Q</link><description></description><content:encoded><![CDATA[乐普生物差异化PD-1单抗，临床优势初显]]></content:encoded><pubDate>Mon, 07 Jun 2021 06:56:04 +0800</pubDate></item><item><title>ASCO：鱼叉断</title><link>https://mp.weixin.qq.com/s/AIQ4P-K2xosTvEOD8K_Jug</link><description></description><content:encoded><![CDATA[ASCO：鱼叉断]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>索马鲁肽获FDA批准治疗肥胖症</title><link>https://mp.weixin.qq.com/s/SqunFmLSwrq1OxZ4QwAg_Q</link><description></description><content:encoded><![CDATA[索马鲁肽获FDA批准治疗肥胖症]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>荣昌生物即将申报Claudin 18.2 ADC</title><link>https://mp.weixin.qq.com/s/B8V7JSxyGZUA-52DaCnTpQ</link><description></description><content:encoded><![CDATA[荣昌生物即将申报Claudin 18.2 ADC]]></content:encoded><pubDate>Sat, 05 Jun 2021 06:41:20 +0800</pubDate></item><item><title>岸迈生物研发PD-L1/TGFβ双抗</title><link>https://mp.weixin.qq.com/s/QynXlovSmsgudMJT4vTgMw</link><description></description><content:encoded><![CDATA[岸迈生物研发PD-L1/TGFβ双抗]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>恒瑞医药一季度营收69亿元，增幅25%</title><link>https://mp.weixin.qq.com/s/u1foiRLCFAIYKxJUmsXhww</link><description></description><content:encoded><![CDATA[恒瑞医药一季度营收69亿元，增幅25%]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>Nature：IgM新冠中和抗体</title><link>https://mp.weixin.qq.com/s/B845YHV0HGYzKoa4YJM4sQ</link><description></description><content:encoded><![CDATA[Nature：IgM新冠中和抗体]]></content:encoded><pubDate>Fri, 04 Jun 2021 09:12:07 +0800</pubDate></item><item><title>ASCO：新型肿瘤疫苗脱颖而出</title><link>https://mp.weixin.qq.com/s/2K_8CjTW4YfoeQwJDdMWDg</link><description></description><content:encoded><![CDATA[ASCO：新型肿瘤疫苗脱颖而出]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>ASCO：纳米药物NBTXR3逆转PD-1抵抗，联拓拥有中国权益</title><link>https://mp.weixin.qq.com/s/GfW7XcqLYjKMdM_fPTGPSQ</link><description></description><content:encoded><![CDATA[ASCO：纳米药物NBTXR3逆转PD-1抵抗，联拓拥有中国权益]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>岸迈生物申报BCMA/CD3双抗</title><link>https://mp.weixin.qq.com/s/oKYhNKQlx-ACOJ04fu850w</link><description></description><content:encoded><![CDATA[岸迈生物申报BCMA/CD3双抗]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>国内第7家：博际生物PD-L1/TGFβ双抗获FDA批准临床</title><link>https://mp.weixin.qq.com/s/7FUTog76iaLbGaynNvz8_w</link><description></description><content:encoded><![CDATA[国内第7家：博际生物PD-L1/TGFβ双抗获FDA批准临床]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>8.8亿美元：Genmab与Bolt合作开发3款肿瘤免疫ADC药物</title><link>https://mp.weixin.qq.com/s/QAhlsDlvulF3T1XnMJHy9A</link><description></description><content:encoded><![CDATA[8.8亿美元：Genmab与Bolt合作开发3款肿瘤免疫ADC药物]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>Morphosys 17亿美元收购Constellation</title><link>https://mp.weixin.qq.com/s/7oQ3jSbFVefHJmHdH6Ujnw</link><description></description><content:encoded><![CDATA[Morphosys 17亿美元收购Constellation]]></content:encoded><pubDate>Thu, 03 Jun 2021 13:37:40 +0800</pubDate></item><item><title>2021年最受期待10大新药，再鼎买了俩</title><link>https://mp.weixin.qq.com/s/pcdEG8MQrgTaKowkOln-ww</link><description></description><content:encoded><![CDATA[2021年最受期待10大新药，再鼎买了俩]]></content:encoded><pubDate>Wed, 02 Jun 2021 06:26:27 +0800</pubDate></item></channel></rss>